(Reuters) – The U.S. government’s Medicare program on Tuesday said it plans to cover Alzheimer’s treatments including Biogen Inc’s Aduhelm, with some conditions.
The agency said that it plans to provide coverage for the drug only if they are enrolled in qualifying clinical trials.
(Reporting by Leroy Leo; Editing by Devika Syamnath)
